Upgrade to SI Premium - Free Trial

Kura Oncology (KURA)

9.61 -0.25 (2.54%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/29/26)

Latest Headlines

Kura Oncology (KURA) Reiterated at Overweight by Cantor Fitzgerald After Webinar on KO-7246 October 14, 2026 7:19 AM - StreetInsider Kura Oncology (KURA) Reiterated at Market Outperform by Citizens on Preclinical Data for KO-7246 October 14, 2026 4:17 AM - StreetInsider Kura Oncology and Caspian outline diabetes drug development plan October 13, 2026 7:31 AM - StreetInsider Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes October 13, 2026 7:30 AM - Globe NewsWire Caspian Therapeutics and Kura Oncology to host investor webcast October 7, 2026 7:15 AM - StreetInsider Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes October 7, 2026 7:15 AM - Globe NewsWire UBS Reiterates Buy Rating on Kura Oncology (KURA) October 5, 2026 5:37 AM - StreetInsider Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 2, 2026 7:30 AM - Globe NewsWire JPMorgan Starts Kura Oncology (KURA) at Overweight October 1, 2026 2:43 AM - StreetInsider Form 4 Kura Oncology, Inc. For: Sep 28 Filed by: Bair Teresa Brophy September 29, 2026 6:30 PM - SEC Filing Form 4 Kura Oncology, Inc. For: Sep 28 Filed by: Powl Brian T. September 29, 2026 6:30 PM - SEC Filing Form 4 Kura Oncology, Inc. For: Sep 28 Filed by: DOYLE THOMAS JAMES September 29, 2026 6:30 PM - SEC Filing Form 4 Kura Oncology, Inc. For: Sep 28 Filed by: Leoni Mollie September 29, 2026 6:30 PM - SEC Filing Form 4 Kura Oncology, Inc. For: Sep 28 Filed by: FORD KATHLEEN September 29, 2026 6:30 PM - SEC Filing Form 144 Kura Oncology, Inc. Filed by: Powl Brian T. September 29, 2026 4:26 PM - SEC Filing Form 144 Kura Oncology, Inc. Filed by: Leoni Mollie September 29, 2026 4:25 PM - SEC Filing Form 144 Kura Oncology, Inc. Filed by: FORD KATHLEEN September 29, 2026 4:25 PM - SEC Filing Caspian Therapeutics shares preclinical data on KO-7246 for diabetes September 29, 2026 6:03 AM - StreetInsider Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes September 29, 2026 5:15 AM - Globe NewsWire Form 144 Kura Oncology, Inc. Filed by: Powl Brian T. September 28, 2026 9:00 PM - SEC Filing Form 144 Kura Oncology, Inc. Filed by: FORD KATHLEEN September 28, 2026 8:00 PM - SEC Filing Form 144 Kura Oncology, Inc. Filed by: Bair Teresa Brophy September 28, 2026 8:00 PM - SEC Filing Form 144 Kura Oncology, Inc. Filed by: Leoni Mollie September 28, 2026 8:00 PM - SEC Filing Form 144 Kura Oncology, Inc. Filed by: DOYLE THOMAS JAMES September 28, 2026 8:00 PM - SEC Filing Form 144 Kura Oncology, Inc. Filed by: Powl Brian T. September 28, 2026 4:21 PM - SEC Filing Form 4 Kura Oncology, Inc. For: Sep 24 Filed by: Burrows Francis September 25, 2026 4:05 PM - SEC Filing Form 144 Kura Oncology, Inc. Filed by: Burrows Francis September 24, 2026 4:06 PM - SEC Filing Form 4 Kura Oncology, Inc. For: Sep 08 Filed by: Fulk Jennifer September 10, 2026 4:30 PM - SEC Filing Form 3 Kura Oncology, Inc. For: Sep 08 Filed by: Fulk Jennifer September 10, 2026 4:25 PM - SEC Filing Form 4 Kura Oncology, Inc. For: Aug 21 Filed by: Powl Brian T. August 24, 2026 5:30 PM - SEC Filing Form 4 Kura Oncology, Inc. For: Aug 24 Filed by: WILSON TROY EDWARD August 24, 2026 5:30 PM - SEC Filing Kura Oncology (KURA) Reiterated at Market Outperform by Citizens Post Q2 Results August 24, 2026 4:13 AM - StreetInsider Form 144 Kura Oncology, Inc. Filed by: Powl Brian T. August 21, 2026 4:41 PM - SEC Filing Form 4 Kura Oncology, Inc. For: Aug 19 Filed by: Bair Teresa Brophy August 21, 2026 4:31 PM - SEC Filing Form 144 Kura Oncology, Inc. Filed by: Bair Teresa Brophy August 19, 2026 4:24 PM - SEC Filing Form 4 Kura Oncology, Inc. For: Aug 17 Filed by: WILSON TROY EDWARD August 17, 2026 4:45 PM - SEC Filing Form SCHEDULE 13G/A Kura Oncology, Inc. Filed by: MONTANOVA CAPITAL, LLC August 14, 2026 4:32 PM - SEC Filing Form 10-Q Kura Oncology, Inc. For: Jun 30 August 12, 2026 4:16 PM - SEC Filing Form 8-K Kura Oncology, Inc. For: Aug 12 August 12, 2026 4:10 PM - SEC Filing Kura Oncology (KURA) Tops Q2 EPS by 11c, Beats on Revenue August 12, 2026 4:05 PM - StreetInsider Kura Oncology Reports Second Quarter 2026 Financial Results August 12, 2026 4:02 PM - Globe NewsWire Kura Oncology publishes ziftomenib preclinical data in Blood journal August 10, 2026 8:36 AM - StreetInsider Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity August 10, 2026 8:32 AM - Globe NewsWire Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 7, 2026 7:30 AM - Globe NewsWire Kura Oncology to Report Second Quarter Financial Results August 5, 2026 7:30 AM - Globe NewsWire Form 8-K Kura Oncology, Inc. For: Jul 24 July 29, 2026 5:07 PM - SEC Filing Kura Oncology reports Phase 1a data on darlifarnib combo in RCC July 27, 2026 6:32 AM - StreetInsider Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 July 27, 2026 6:32 AM - Globe NewsWire Full Article List